spacerspacerspacerspacerspacer
Center for BiosecurityUPMC | University of Pittsburgh Medical Center

Give us feedback | Search | Sitemap | Home

horizontal rulespacer


Areas of Focus

  
Special Topics   
Resources The Center

 

This Website is supported by funding from the Alfred P. Sloan Foundation.
Home > Biosecurity News in Brief > Archive > Countermeasure Development
Tools:||Link to this page| Share this page
horizontal rule
spacer

Biosecurity News in Brief

Subscribe | About | Current Issue | RSS | Archive

Countermeasure Development Archive

Anthrax | Smallpox | Influenza | General

Anthrax

Bio Briefing - Countermeasures: Anthrax

Biosecurity Briefing articles relating to anthrax countermeasure developments.

  1. NIAID, BARDA Award Anthrax Vaccine Contracts, Ebola/Marburg Contracts (10-06-2008)

    Biosecurity Briefing: NIAID, BARDA awarded contracts to develop a next generation anthrax vaccine, as well as two contracts for development of a multivalent Ebola and Marburg vaccine.
    Tue, 07 Oct 2008 15:55:10 GMThttp://www.upmc-biosecurity.org/website/biosecurity_briefing/archive/countrmeasr_dev/2008/2008-10-06-niaidbardavaccontracts.html

  2. HHS Takes Preparedness Measures for Anthrax; Requests Antibiotic Kit EUA for Postal Carriers, Liability Protection for Private Sector Businesses (10-06-2008)

    Biosecurity Briefing: HHS announced that the dept. has called for 2 measures to prepare for an anthrax attack--issue kits containing antibiotics for postal workers and liability protections for private sector businesses engaged in some cntr. measures.
    Mon, 06 Oct 2008 21:02:38 GMThttp://www.upmc-biosecurity.org/website/biosecurity_briefing/archive/countrmeasr_dev/2008/2008-10-06-hhsprepanthrax.html

  3. BARDA, NIAID Award Anthrax Monoclonal Antibody Contract; NIAID Awards Botulinum Antitoxin Contract (09-15-2008)

    Biosecurity Briefing: On September 3, 2008, Emergent BioSolutions, Inc., announced that it had been awarded a $24.3 million contract to develop its anthrax monoclonal antibody AVP-21D9. The contract was awarded jointly by BARDA and NIAID.
    Tue, 16 Sep 2008 14:32:36 GMThttp://www.upmc-biosecurity.org/website/biosecurity_briefing/archive/countrmeasr_dev/2008/2008-09-15-anthraxantibodybotulinumantitox.html

  4. India Imports Anthrax Vaccine, Bangladesh Expands Bird Flu Program (06-13-2008)

    Biosecurity Briefing: The Times of India reported that a company in India has imported 200 doses of Biothrax, the only anthrax vaccine approved by the FDA. Xinhua News Agency reported that neighboring Bangladesh is expanding its bird flu prep programs.
    Fri, 13 Jun 2008 20:45:39 GMThttp://www.upmc-biosecurity.org/website/biosecurity_briefing/archive/international_biosecurity/2008-06-13-indiaanthrxvacbangladesh.html

  5. FDA Approves Antimicrobial for Pediatric Inhalational Anthrax Exposure (05-16-2008)

    Biosecurity Briefing: Drug Industry Daily news reports the FDA approved Levaquin (levofloxacin) for use in pediatric patients who have been exposed to Bacillus anthracis. This is the first and only pediatric indication for Levaquin.
    Fri, 16 May 2008 19:23:46 GMThttp://www.upmc-biosecurity.org/website/biosecurity_briefing/archive/countrmeasr_dev/2008/2008-05-16-fdaapprovantimicrobialpedathrax.html

  6. HHS Requests Proposals for Next Anthrax Vaccine (03-07-2008)

    Biosecurity Briefing: CQ Politics reported that the HHS released a request for proposals (RFP) for development of a new anthrax vaccine. The RFP requires 25 million doses of a vaccine that can be administered in only three doses.
    Mon, 10 Mar 2008 14:57:04 GMThttp://www.upmc-biosecurity.org/website/biosecurity_briefing/archive/countrmeasr_dev/2008/2008-03-07-hhsrfpanthraxvac.html

  7. House Committee Concerned About Timeline for Acquisition of Anthrax Countermeasures (09-14-2007)

    Biosecurity Briefing: The House Committee on Homeland Security expressed disappointment regarding the pace with which the agency has moved toward the development and procurement of a recombinant protective antigen anthrax vaccine.
    Fri, 14 Sep 2007 21:03:00 GMThttp://www.upmc-biosecurity.org/website/biosecurity_briefing/archive/countrmeasr_dev/content/2007/2007-09-14-housecomtimeanthraxcounter.html

  8. Study Shows New Adjuvant, Nasal Spray Vaccine May Offer Protection against Anthrax (08-24-2007)

    Biosecurity Briefing: According to a study in Infection and Immunity, anthrax vaccine with a new adjuvant administered nasally provided guinea pigs greater protection against lethal doses of anthrax than the standard vaccine administered by injection.
    Fri, 24 Aug 2007 21:03:00 GMThttp://www.upmc-biosecurity.org/website/biosecurity_briefing/archive/countrmeasr_dev/content/2007/2007-08-24-studyshowsnewadjuvantprotectagainstanthrax.html

  9. Candidate Anthrax Treatment Receives Orphan Drug Designation (03-10-2006)

    Biosecurity Briefing: On March 6, Medarex, Inc. and PharmAthene, Inc. announced that the U.S. Food and Drug Administration (FDA) has granted orphan-drug designation to Valortim� (MDX- 1303).
    Wed, 31 Jan 2007 16:22:30 GMThttp://www.upmc-biosecurity.org/website/biosecurity_briefing/archive/agents_diseases/content/anthrax/2006-03-10-candidateanthraxtrtmtgetsor.html

  10. HHS Extends VaxGen's Deadline to Resolve Clinical Hold on Anthrax Vaccine (11-17-2006)

    Biosecurity Briefing: VaxGen announced that the US Dept of Health and Human Services (HHS) has extended by more than a month the deadline for VaxGen to resolve the clinical hold placed on its anthrax vaccine trials by the Food and Drug Administration.
    Fri, 17 Nov 2006 19:11:00 GMThttp://www.upmc-biosecurity.org/website/biosecurity_briefing/archive/agents_diseases/content/anthrax/2006-11-17-hhsvaxgendeadline.html

  11. Delays in Anthrax Vaccine Delivery Raise Concerns about BioShield Process (08-18-2006)

    Biosecurity Briefing: The San Jose, CA Mercury News reports recent concerns about delivery of a new anthrax vaccine being developed by VaxGen and funded by the Department of Health and Human Services (HHS).
    Fri, 18 Aug 2006 16:22:00 GMThttp://www.upmc-biosecurity.org/website/biosecurity_briefing/archive/agents_diseases/content/anthrax/2006-08-18-anthraxvxdeliverydelays.html

  12. HHS Buys Additional Anthrax Therapeutic for the SNS (07-28-2006)

    Biosecurity Briefing: On July 28, HHS announced that it had awarded a $143,833,719 contract to Cangene Corporation (Cangene) for the purchase of 10,000 therapeutic courses of Anthrax Immune Globulin (AIG) for the Strategic National Stockpile (SNS).
    Fri, 28 Jul 2006 16:22:00 GMThttp://www.upmc-biosecurity.org/website/biosecurity_briefing/archive/agents_diseases/content/anthrax/2006-07-28-hhsbuysaddlanthxtherapforsns.html

  13. HHS Purchases Anthrax Therapeutic for the SNS; Development of Additional Candidate Anthrax Therapeutics Continues (06-23-2006)

    Biosecurity Briefing: On June 20, the U.S. Department of Health and Human Services (HHS) announced that it has exercised the option under its contract with Human Genome Sciences, Inc. (HGS) to purchase ABthraxTM for the Strategic National Stockpile (SNS).
    Fri, 23 Jun 2006 16:22:00 GMThttp://www.upmc-biosecurity.org/website/biosecurity_briefing/archive/agents_diseases/content/anthrax/2006-06-23-hhspurchasesanthraxtherapeuticforSNS.html

  14. New Anthrax Vaccine with Improved Stability Sought (06-19-2006)

    Biosecurity Briefing: On June 12, Avecia Biotechnology announced that it had received a $3.9 million grant from the U.S. National Institute of Allergy and Infectious Diseases to develop an anthrax vaccine with "improved stability."
    Mon, 19 Jun 2006 16:22:00 GMThttp://www.upmc-biosecurity.org/website/biosecurity_briefing/archive/agents_diseases/content/anthrax/2006-06-19-newnanthraxvaccinewithimprovedstabilitysought.html

  15. FDA Issues Warning to VaxGen Regarding its Anthrax Vaccine (03-31-2006)

    Biosecurity Briefing: On April 4, the USDA's Office of Compliance and Biologics Quality (OCBQ) made public a warning letter it sent to VaxGen, Inc. on March 24, 2006, regarding VaxGen's candidate anthrax vaccine (rPA102).
    Fri, 31 Mar 2006 16:22:00 GMThttp://www.upmc-biosecurity.org/website/biosecurity_briefing/archive/agents_diseases/content/anthrax/2006-03-31-fdaissueswarningtovaxgenreg.html

  16. Pentagon Releases Report on Response to March 2005 Anthrax Incidents (03-31-2006)

    Biosecurity Briefing: According to a March 24 Department of Defense (DoD) press release, the RAND Corporation delivered an assessment to the Pentagon on the department's response to three suspected anthrax incidents that occurred in March 2005.
    Fri, 31 Mar 2006 16:22:00 GMThttp://www.upmc-biosecurity.org/website/biosecurity_briefing/archive/agents_diseases/content/anthrax/2006-03-31-pentagonreleasesreportonmar.html

  17. VaxGen Responds to Concerns About its Anthrax Vaccine (03-24-2006)

    Biosecurity Briefing: On March 17, VaxGen responded to a recent Washington Post report that VaxGen has encountered problems with its anthrax vaccine, rPA102, that may delay its delivery to the government for the Strategic National Stockpile.
    Fri, 24 Mar 2006 16:22:00 GMThttp://www.upmc-biosecurity.org/website/biosecurity_briefing/archive/agents_diseases/content/anthrax/2006-03-24-vaxgenrespondstoconcernsabo.html

  
[return to top]

Smallpox

Bio Briefing - Countermeasures: Smallpox

Biosecurity Briefing articles relating to smallpox countermeasure developments.

  1. New Smallpox Vaccine Safe for HIV Patients (11-24-2008)

    Biosecurity Briefing: On November 5, 2008, the Danish pharmaceutical company Bavarian Nordic reported that its new smallpox vaccine, Imvamune, is safe for use in patients infected with HIV.
    Tue, 25 Nov 2008 19:14:23 GMThttp://www.upmc-biosecurity.org/website/biosecurity_briefing/archive/countrmeasr_dev/2008/2008-11-24-smallpxvacsafehiv.html

  2. NIAID Awards Additional Funding for Smallpox Antiviral; DTRA Awards $8.3 Million for Research into Broad-Spectrum Antibiotics (09-29-2009)

    Biosecurity Briefing: SIGA Tech. received an award from NIAID to accelerate development of its smallpox antiviral drug ST-246. SRI Intl announced DoD�s DTRA awarded contract to facilitate preclinical research in developing broad spectrum antibiotics.
    Mon, 29 Sep 2008 20:48:47 GMThttp://www.upmc-biosecurity.org/website/biosecurity_briefing/archive/countrmeasr_dev/2008/2008-09-29-niaidfundsmallpxantiviral.html

  3. NIAID and BARDA Award Funding to SIGA Technologies for Orthopoxvirus Antiviral (09-08-2008)

    Biosecurity Briefing: SIGA Technologies, Inc., announced that NIAID and HHS BARDA awarded the pharmaceutical company a $55 million contract to fund the development of additional formulations and smallpox-related indications for its antiviral drug ST-246.
    Tue, 09 Sep 2008 15:53:50 GMThttp://www.upmc-biosecurity.org/website/biosecurity_briefing/archive/countrmeasr_dev/2008/2008-09-08-fundssigatechantiviral.html

  4. Acambis Wins USG Contract for Smallpox Vaccine (04-25-2008)

    Biosecurity Briefing: Reuters reported that British vaccine developer Acambis won a $425 million, 10-year contract to supply the U.S. govt with 9 million doses of the ACAM2000 smallpox vac. each year for delivery to the Strategic National Stockpile.
    Fri, 25 Apr 2008 20:51:43 GMThttp://www.upmc-biosecurity.org/website/biosecurity_briefing/archive/agents_diseases/smallpox/2008-04-25-acambisusgsmallpoxvac.html

  5. Study Shows Smallpox Vaccine Effective in Diluted Doses (02-16-2007)

    Biosecurity Briefing: The March 15, 2007 edition of the Journal of Infectious Diseases published a study conducted to determine if diluted doses of smallpox vaccine offers effective protection from the disease.
    Tue, 20 Feb 2007 18:57:11 GMThttp://www.upmc-biosecurity.org/website/biosecurity_briefing/archive/agents_diseases/content/smallpox/2007-02-16-studysmallpxvaceffectivesmdose.html

  6. Progress on Development of 3rd Generation Smallpox Vaccines (03-03-2006)

    Biosecurity Briefing: Among the abstracts presented at the ASM Biodefense Research Meeting were several pertaining to the development of potentially safer smallpox vaccines
    Wed, 31 Jan 2007 19:15:40 GMThttp://www.upmc-biosecurity.org/website/biosecurity_briefing/archive/agents_diseases/content/smallpox/2006-03-03-progressondevelof3rdgensmal.html

  7. Study Finds Greater Risks Associated with European Smallpox Vaccine (09-08-2006)

    Biosecurity Briefing: On August 22, 2006, the journal Public Library of Science (PLoS) Medicine published a study indicating that the European smallpox vaccine may have higher morbidity and mortality to than the U.S. vaccine due to differences in strain.
    Fri, 08 Sep 2006 16:22:00 GMThttp://www.upmc-biosecurity.org/website/biosecurity_briefing/archive/agents_diseases/content/smallpox/2006-09-08-risksassociatedeuropeanvacc.html

  8. Recent Discoveries May Lead to New Smallpox Treatment and SARS Vaccine (08-11-2006)

    Biosecurity Briefing: In an August 4 news release, researchers at the University of Pennsylvania School of Medicine announced the discovery of a smallpox virus enzyme which may provide clues to the development of new drugs to target the virus.
    Fri, 11 Aug 2006 16:22:00 GMThttp://www.upmc-biosecurity.org/website/biosecurity_briefing/archive/agents_diseases/content/smallpox/2006-08-11-recentdiscovsmpxSARS.html

  9. HHS Amends Request for Proposal for Third Generation Smallpox Vaccine (07-28-2006)

    Biosecurity Briefing: On July 24, HHS issued an amendment to its request for proposal (RFP) for the acquisition of third generation smallpox vaccine based on modified vaccinia Ankara (MVA) for the Strategic National Stockpile (SNS).
    Fri, 28 Jul 2006 19:18:00 GMThttp://www.upmc-biosecurity.org/website/biosecurity_briefing/archive/agents_diseases/content/smallpox/2006-07-28-hhsamendsrfpfor3rdgensmpxvx.html

   
[return to top]

Influenza

Bio Briefing - Countermeasures: Influenza

Biosecurity Briefing articles relating to flu countermeasure developments.

  1. Novartis H5N1 Vaccine Produces Rapid Immunity When Primed With H5N3 Vaccine (10-27-2008)

    Biosecurity Briefing: A study published in the October 9, 2008, issue of the New England Journal of Medicine evaluates the Novartis H5N1 influenza vaccine, which employs a prime-boost strategy to induce immunity.
    Mon, 27 Oct 2008 20:55:28 GMThttp://www.upmc-biosecurity.org/website/biosecurity_briefing/archive/avian_pandemic_flu/2008/2008-10-27-novartish5n1vacwithh5n3vac.html

  2. Countermeasure Research and Development News Updates (09-22-2008)

    Biosecurity Briefing: GSK results of trials for its pre-pandemic H5N1 vaccine Prepandrix. Vaxin, Inc., announced NIH awarded grant for ongoing development of avian flu vac for poultry. XOMA, Ltd., announced establishment of a MOU with Texas A&M System.
    Mon, 22 Sep 2008 16:02:07 GMThttp://www.upmc-biosecurity.org/website/biosecurity_briefing/archive/countrmeasr_dev/2008/2008-09-22-cntrmeasureranddnews.html

  3. Survey Finds H5N1 Knowledge Low in Afghanistan; Novavax Pandemic Vaccine Promising in Clinical Trial (09-08-2008)

    Biosecurity Briefing: CDC survey assessed factors that affect the knowledge regarding H5N1 in Afghanistan. Novavax, Inc. announced positive results from the 2nd stage of human clinical trial of its pandemic flu virus-like particle vac candidate.
    Tue, 09 Sep 2008 15:32:26 GMThttp://www.upmc-biosecurity.org/website/biosecurity_briefing/archive/avian_pandemic_flu/2008/2008-09-08-h5n1knowledgelownovavaxpanvac.html

  4. WHO Reports Oseltamivir Resistance in Southern Hemisphere (08-25-2008)

    Biosecurity Briefing: On August 15, 2008, the World Health Organization (WHO) issued a report indicating that clinical samples from the 2008 influenza season provide evidence of a high degree of resistance to the antiviral drug oseltamivir (Tamiflu).
    Mon, 25 Aug 2008 16:32:51 GMThttp://www.upmc-biosecurity.org/website/biosecurity_briefing/archive/avian_pandemic_flu/2008/2008-08-25-whooseltamivirresistsohemisphere.html

  5. BARDA Announces RFP for H5N1 Vaccine (07-28-2008)

    Biosecurity Briefing: Biomedical Advanced Research and Development Authority (BARDA) announced a RFP for an egg-based inactivated monovalent H5N1 vaccine at commercial scale for inclusion in the Strategic National Stockpile.
    Mon, 28 Jul 2008 21:21:24 GMThttp://www.upmc-biosecurity.org/website/biosecurity_briefing/archive/countrmeasr_dev/2008/2008-07-28-bardarfph5n1vac.html

  6. H5N1 News: Australia Approves Vaccine; Sanofi to Donate to WHO Stockpile; HHS Contracts to Develop Rapid Diagnostic Tests (06-20-2008)

    Biosecurity Briefing: Australia approves H5N1 vaccine Panvax, developed by CSL Limited; Sanofi to donate to WHO stockpile to help poor countries; HHS contracts to develop low-cost rapid diagnostic tests for influenza.
    Fri, 20 Jun 2008 20:38:02 GMThttp://www.upmc-biosecurity.org/website/biosecurity_briefing/archive/avian_pandemic_flu/2008/2008-06-20-h5n1newsaustraliasanofihhs.html

  7. Indonesia Reduces H5N1 Case Reporting to Once Every 6 Months, Accuses Baxter of Delaying Vaccine (06-13-2008)

    Biosecurity Briefing: A Reuters article describes Indonesia's new avian influenza reporting policy, which will now require human cases of avian influenza to be reported once every six months rather than immediately upon recognition.
    Fri, 13 Jun 2008 21:00:17 GMThttp://www.upmc-biosecurity.org/website/biosecurity_briefing/archive/international_biosecurity/2008-06-13-indonesiareducesh5n1reportng.html

  8. WHO Document Guides Strategic Use of H5N1 Vaccine and Vaccine Stockpile (05-23-2008)

    Biosecurity Briefing: On May 16, 2008, the World Health Organization (WHO) released a document that discusses options for human use of H5N1 influenza vaccine as well as options for use of the WHO H5N1 vaccine stockpile.
    Fri, 23 May 2008 19:55:13 GMThttp://www.upmc-biosecurity.org/website/biosecurity_briefing/archive/countrmeasr_dev/2008/2008-05-23-whoguideh5n1vacstock.html

  9. EU Grants Marketing License for Pre-Pandemic Flu Vaccine (05-23-2008)

    Biosecurity Briefing: The Associated Press reported that GlaxoSmithKline has been granted a marketing license by the European Commission to begin distributing the first "pre-pandemic" influenza vaccine to hit the European market.
    Fri, 23 May 2008 19:40:34 GMThttp://www.upmc-biosecurity.org/website/biosecurity_briefing/archive/countrmeasr_dev/2008/2008-05-23-eulicenseprepanfluvac.html

  10. HHS Spends $192.5 Million on H5N1 Vaccine (05-02-2008)

    Biosecurity Briefing: CIDRAP reported that the HHS purchased $192.5 million worth of clade 2.2 H5N1 vaccine from sanofi pasteur. The purchase will provide 6.4 to 38.5 million doses of the vaccine to the Strategic National Stockpile (SNS).
    Mon, 05 May 2008 16:20:01 GMThttp://www.upmc-biosecurity.org/website/biosecurity_briefing/archive/govt_response/2008-05-02-hhsspends192mh5n1vaccine.html

  11. H5N1 Vaccine Adjuvant Patch Enters Phase II Trials (04-18-2008)

    Biosecurity Briefing: Reuters reported that Iomai, a small Gaithersburg, MD, biotechnology company, received "U.S. [Department of Health and Human Services] approval..." to begin phase II clinical trials testing "a bird flu skin patch on more people."
    Fri, 18 Apr 2008 19:55:36 GMThttp://www.upmc-biosecurity.org/website/biosecurity_briefing/archive/countrmeasr_dev/2008/2008-04-18-h5n1vacadjuvantpatchphase2.html

  12. First Pre-Pandemic Flu Vaccine Recommended for EU-Wide Marketing License (03-07-2008)

    Biosecurity Briefing: The European Medicines Agency, equivalent of U.S. FDA, announced that it recommends "the authorization of...[Europe's] first 'pre-pandemic vaccine' for humans against influenza caused by the H5N1 virus."
    Mon, 10 Mar 2008 16:20:39 GMThttp://www.upmc-biosecurity.org/website/biosecurity_briefing/archive/international_biosecurity/2008-03-07-1stprepanfluvaceulicense.html

  13. Flu Season Marked by Vaccine Mismatch, Antiviral Resistance in Europe (02-15-2008)

    Biosecurity Briefing: CDC reports seasonal flu more severe than last 2 years and a mismatch between this year's vac and two of predominant strains of flu. Europe reports unexpected emergence of H1N1 virus with a decreased sensitivity to oseltamivir.
    Tue, 19 Feb 2008 15:31:18 GMThttp://www.upmc-biosecurity.org/website/biosecurity_briefing/archive/avian_pandemic_flu/2008/2008-02-15-fluvacmismatchresisteurope.html

  14. New Under-the-Tongue Influenza Vaccination Method Studied (02-01-2008)

    Biosecurity Briefing: On January 29, 2008, the International Vaccine Institute (IVI) reported the results of a study that examines a new way of delivering influenza vaccines: sublingually, or under the tongue.
    Fri, 01 Feb 2008 20:40:49 GMThttp://www.upmc-biosecurity.org/website/biosecurity_briefing/archive/countrmeasr_dev/2008/2008-02-01-newundertonguefluvacstudy.html

  15. Tamiflu Resistance Found Throughout Europe (02-01-2008)

    Biosecurity Briefing: The European Centre for Disease Prevention and Control reported that "some of the A (H1N1) viruses in circulation this winter are resistant to the antiviral drug oseltamivir (also know by the brand name Tamiflu)."
    Fri, 01 Feb 2008 20:39:52 GMThttp://www.upmc-biosecurity.org/website/biosecurity_briefing/archive/international_biosecurity/2008-02-01-tamifluresistancefound.html

  16. Gates Foundation Awards $39 Million to Develop Flu Vaccines for Resource Poor Countries (01-18-2008)

    Biosecurity Briefing: PATH, an international, non-profit organization, announced a $39 million award from the Bill & Melinda Gates foundation to launch the rapid development of flu vaccines and "innovative vaccine technologies" for developing nations.
    Tue, 22 Jan 2008 13:35:13 GMThttp://www.upmc-biosecurity.org/website/biosecurity_briefing/archive/avian_pandemic_flu/2008/2008-01-18-gatesawardsmillionsfluvac.html

  17. HHS Announces CBRN Advisory Board and Pandemic Vaccine Contracts (06-22-2007)

    Biosecurity Briefing: HHS Secretary Mike Leavitt announced that the agency has established a public health advisory board to provide guidance on chemical, biological, radiological and nuclear (CBRN) threats. He also announced contracts for flu vaccine.
    Fri, 22 Jun 2007 20:36:01 GMThttp://www.upmc-biosecurity.org/website/biosecurity_briefing/archive/govt_response/content/2007-06-22-hhscbrnadvisorybrdvaxcontracts.html

  18. Prior Immunity to Seasonal Flu May be Partial Protection H5N1 (02-16-2007)

    Biosecurity Briefing: In the February 2007 edition of the Public Library of Science (PLoS) Medicine journal, a study investigated whether immunity to the human seasonal influenza strain, H1N1, may confer immunity to the avian influenza virus, H5N1.
    Fri, 16 Feb 2007 17:16:00 GMThttp://www.upmc-biosecurity.org/website/biosecurity_briefing/archive/avian_pandemic_flu/content/2007/2007-02-16-researchpriorimmunityflu.html

  19. Indonesia to Share Virus for Vaccine; New H5N1 Cases in Turkey, Egypt (02-16-2007)

    Biosecurity Briefing: On Feb 16, 2007 the AP reported that Indonesia will share H5N1 virus samples with WHO only if developing countries are guaranteed equal access to affordable vaccine once it is produced. Also, Turkey and Egypt report H5N1.
    Fri, 16 Feb 2007 17:13:00 GMThttp://www.upmc-biosecurity.org/website/biosecurity_briefing/archive/avian_pandemic_flu/content/2007/2007-02-16-indonesiasharesampforvac.html

  
[return to top]

General

Bio Briefing - Countermeasures: General

Biosecurity Briefing articles relating to general countermeasure developments.

  1. Draft of National Vaccine Plan Released (12-15-2008)

    Biosecurity Briefing: On December 4, 2008, HHS released a draft of its national vaccine strategy, a plan intended to guide the federal government in making policy decisions on vaccine development, production, and distribution.
    Mon, 15 Dec 2008 20:27:15 GMThttp://www.upmc-biosecurity.org/website/biosecurity_briefing/archive/govt_response/2008-12-15-draftnatlvacplan.html

  2. FDA Opening Offices Overseas to Address Food and Drug Safety (10-20-2008)

    Biosecurity Briefing: HHS announced plans to send U.S. Food and Drug Administration (FDA) staff to new offices in China, India, Europe, and Latin America as part of efforts to "enhance the safety of imported food and medical products."
    Mon, 20 Oct 2008 20:17:30 GMThttp://www.upmc-biosecurity.org/website/biosecurity_briefing/archive/countrmeasr_dev/2008/2008-10-20-fdaoverseas.html

  3. NIAID, BARDA Award Anthrax Vaccine Contracts, Ebola/Marburg Contracts (10-06-2008)

    Biosecurity Briefing: NIAID, BARDA awarded contracts to develop a next generation anthrax vaccine, as well as two contracts for development of a multivalent Ebola and Marburg vaccine.
    Tue, 07 Oct 2008 15:55:10 GMThttp://www.upmc-biosecurity.org/website/biosecurity_briefing/archive/countrmeasr_dev/2008/2008-10-06-niaidbardavaccontracts.html

  4. NIAID Awards Additional Funding for Smallpox Antiviral; DTRA Awards $8.3 Million for Research into Broad-Spectrum Antibiotics (09-29-2009)

    Biosecurity Briefing: SIGA Tech. received an award from NIAID to accelerate development of its smallpox antiviral drug ST-246. SRI Intl announced DoD�s DTRA awarded contract to facilitate preclinical research in developing broad spectrum antibiotics.
    Mon, 29 Sep 2008 20:48:47 GMThttp://www.upmc-biosecurity.org/website/biosecurity_briefing/archive/countrmeasr_dev/2008/2008-09-29-niaidfundsmallpxantiviral.html

  5. DTRA Awards Contract to Study Potential of Cethromycin as Broad-Spectrum Antibiotic (08-18-2008)

    Biosecurity Briefing: Advanced Life Sciences announced the award of a contract from the U.S. Dept of Defense Defense Threat Reduction Agency for advanced development of the antibiotic cethromycin as a potential broad-spectrum medical countermeasure.
    Mon, 18 Aug 2008 14:38:59 GMThttp://www.upmc-biosecurity.org/website/biosecurity_briefing/archive/countrmeasr_dev/2008/2008-08-18-dtracontractcethromycin.html

  6. Emergent BioSolutions Wins NIAID Grants, Sanofi to Acquire Acambis (08-04-2008)

    Biosecurity Briefing: Emergent BioSolutions, Inc., announced it has been awarded two grants from NIAID for the development of botulism and next-generation anthrax vaccine candidates. AP reported that sanofi-aventis will acquire vaccine-maker Acambis PLC.
    Mon, 04 Aug 2008 16:15:47 GMThttp://www.upmc-biosecurity.org/website/biosecurity_briefing/archive/agents_diseases/other/2008-08-04-emergentniaidsanofiacambis.html

  7. FDA Changes Process for Product Licensure Notification (07-11-2008)

    Biosecurity Briefing: The FDA issued a news release announcing a change in the format of letters that are sent to pharmaceutical companies to inform them of the FDA's decision regarding licensure of pharmaceutical products.
    Mon, 14 Jul 2008 14:21:02 GMThttp://www.upmc-biosecurity.org/website/biosecurity_briefing/archive/govt_response/2008-07-11-fdaproductlicensenotice.html

  8. Annual Report on Project BioShield Released to Congress (07-11-2008)

    Biosecurity Briefing: HHS announced that the Annual Report to Congress on Project BioShield had been released. This Congressionally mandated report covers progress for the period from August 2006 through July 2007.
    Mon, 14 Jul 2008 13:38:25 GMThttp://www.upmc-biosecurity.org/website/biosecurity_briefing/archive/countrmeasr_dev/2008/2008-07-11-annualrptbioshield.html

  9. Cangene Delivers Botulism Antitoxin to SNS; DynPort, DoD Developing Plague Vaccine (06-13-2008)

    Biosecurity Briefing: CNW reported that Canadian pharmaceutical company Cangene made a large delivery of botulism antitoxin (BAT) to the U.S. government, intended for integration into the U.S. Strategic National Stockpile (SNS).
    Fri, 13 Jun 2008 21:05:46 GMThttp://www.upmc-biosecurity.org/website/biosecurity_briefing/archive/countrmeasr_dev/2008/2008-06-13-cangenebotulismantitox.html

  10. HHS Announces Director for Biomedical Advanced Research Development Authority (BARDA) (04-18-2008)

    Biosecurity Briefing: On April 14, 2008, the U.S. Department of Health and Human Services (HHS) issued a press release naming Robin Robinson, Ph.D. as the first director of the Biomedical Advanced Research Development Authority (BARDA).
    Fri, 18 Apr 2008 19:45:56 GMThttp://www.upmc-biosecurity.org/website/biosecurity_briefing/archive/govt_response/2008-04-18-hhsannouncedirectorbarda.html

  11. Ebola Virus Made Safe to Work With in Laboratories (01-25-2008)

    Biosecurity Briefing: The Proceedings of the National Academy of Sciences (PNAS) published a study describing the generation of a new research strain of Ebola virus which would be "safe" to handle "outside of a biosafety level-4 facility."
    Mon, 28 Jan 2008 14:56:30 GMThttp://www.upmc-biosecurity.org/website/biosecurity_briefing/archive/agents_diseases/vhf/2008-01-25-ebolasafelaboratories.html

  12. Lower Dose of Vaccine Administered to Broader Population May Reduce Total Number Infected in a Pandemic (06-29-2007)

    Biosecurity Briefing: A paper published PLoS Medicine suggests that infection rates during a flu pandemic could be reduced if more people were vaccinated with lower doses of vaccine rather than if a lesser number of people are vaccinated with full doses.
    Tue, 03 Jul 2007 12:50:23 GMThttp://www.upmc-biosecurity.org/website/biosecurity_briefing/archive/countrmeasr_dev/content/2007/2007-06-29-lowerdoseofvaccine.html

  13. Study Reveals Possibilities for New Botulism Treatments and Countermeasures (01-12-2007)

    Biosecurity Briefing: Dec. 21, 2006, study published in the journal Nature reveals new findings on the molecular mechanisms whereby botulinum neurotoxin, the causative agent of botulism, adheres to nerves and disrupts chemical signaling to muscles.
    Fri, 12 Jan 2007 16:22:00 GMThttp://www.upmc-biosecurity.org/website/biosecurity_briefing/archive/agents_diseases/content/botulism/2007-01-12-studyrevealspossibilitiesnewbotulismtreatments.html

  14. HHS Buys Botulism Antitoxin for SNS (06-02-2006)

    Biosecurity Briefing: On June 1, HHS announced that it has awarded a 5-year, $362,641,105 contract to Cangene Corporation for the delivery of 200,000 doses of Heptavalent Botulism Antitoxin to the Strategic National Stockpile (SNS).
    Fri, 02 Jun 2006 16:22:00 GMThttp://www.upmc-biosecurity.org/website/biosecurity_briefing/archive/agents_diseases/content/botulism/2006-06-02-hhsantitoxin.html

  15. Experimental Marburg Virus Vaccine May Confer Protection against Disease when Administered Post-Exposure (05-01-2006)

    Biosecurity Briefing: A study published April 27 by the journal Lancet found that an experimental vaccine against Marburg haemorrhagic fever may protect against disease when administered after exposure to Marburg virus.
    Mon, 01 May 2006 16:22:00 GMThttp://www.upmc-biosecurity.org/website/biosecurity_briefing/archive/agents_diseases/content/viral_hemorrhagic_fevers/2006-05-01-experimentalmarburgvaxmayco.html

  
[return to top]

  

© 2009 University of Pittsburgh Medical Center. All rights reserved. | About this website